AAPL 169.02 1.2702% MSFT 409.06 0.3656% GOOG 161.1 0.7379% GOOGL 159.13 0.5497% AMZN 176.59 -1.6431% NVDA 796.77 -3.3316% META 493.5 -0.5241% TSLA 162.13 12.0611% TSM 132.97 -0.3448% LLY 732.2 -1.8091% V 275.02 0.332% AVGO 1256.82 0.6108% JPM 193.08 0.4892% UNH 487.3 0.2304% NVO 126.16 -1.9279% WMT 59.87 1.32% LVMUY 171.62 -0.1106% XOM 121.05 0.0165% LVMHF 859.75 -0.3073% MA 462.5 -0.0691%
Last update at 2024-04-11T21:01:17.756561Z
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 47.77M | -35.09400M | -40.37500M | -53.23700M | -47.14700M |
| Minority interest | - | - | - | - | - |
| Net income | 47.76M | -35.09900M | -40.37900M | -53.24000M | -47.14900M |
| Selling general administrative | 25.67M | 30.93M | 36.33M | 45.03M | 20.77M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | -0.82000M | -0.93500M | -0.61600M | -4.51700M | -1.82500M |
| Reconciled depreciation | 1.65M | 1.97M | 1.85M | 1.67M | 0.57M |
| Ebit | -36.63300M | -35.96500M | -40.96300M | -54.20500M | -35.16400M |
| Ebitda | -30.18300M | -30.83000M | -37.07000M | -52.03900M | -34.58900M |
| Depreciation and amortization | 6.45M | 5.13M | 3.89M | 2.17M | 0.57M |
| Non operating income net other | - | - | 3.89M | 3.50M | -9.20300M |
| Operating income | -36.63300M | -35.96500M | -40.96300M | -54.20500M | -35.72700M |
| Other operating expenses | 33.46M | 38.78M | 46.38M | 56.49M | 37.88M |
| Interest expense | 1.15M | 2.29M | 3.31M | 1.20M | 12.56M |
| Tax provision | 0.01M | 0.00500M | 0.00400M | 0.00300M | 0.00200M |
| Interest income | 1.50M | 3.16M | 3.89M | 2.17M | 1.14M |
| Net interest income | 0.35M | 0.87M | 0.59M | 0.97M | -11.42000M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 0.01M | 0.00500M | 0.00400M | 0.00300M | 0.00200M |
| Total revenue | 1.77M | 2.82M | 5.42M | 2.29M | 2.15M |
| Total operating expenses | 30.86M | 35.03M | 40.35M | 49.69M | 33.90M |
| Cost of revenue | 2.59M | 3.75M | 6.03M | 6.81M | 3.98M |
| Total other income expense net | 84.40M | 0.87M | 0.59M | 0.97M | -11.42000M |
| Discontinued operations | -11.37000M | -17.94700M | -17.94700M | -17.94700M | - |
| Net income from continuing ops | 47.76M | -35.09900M | -40.37900M | -53.24000M | -47.14900M |
| Net income applicable to common shares | 42.33M | -35.09900M | -40.37900M | -53.24000M | -47.14900M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 47.49M | 77.89M | 66.30M | 91.36M | 120.53M |
| Intangible assets | 8.82M | - | - | - | - |
| Earning assets | - | - | - | - | - |
| Other current assets | 2.31M | 2.59M | 1.68M | 1.74M | 1.02M |
| Total liab | 25.67M | 113.79M | 122.05M | 132.77M | 116.28M |
| Total stockholder equity | 21.81M | -35.89300M | -55.75000M | -41.41800M | 4.25M |
| Deferred long term liab | - | - | - | - | 3.56M |
| Other current liab | 4.15M | 6.44M | 5.00M | 5.88M | 4.93M |
| Common stock | 0.00800M | 0.14M | 0.10M | 0.08M | 0.08M |
| Capital stock | 0.00800M | 0.14M | 0.10M | 0.08M | 0.08M |
| Retained earnings | -425.82900M | -473.58400M | -438.48500M | -398.10600M | -345.01900M |
| Other liab | 11.90M | 86.52M | 88.66M | 95.01M | 96.97M |
| Good will | - | - | - | - | - |
| Other assets | 22.82M | 2.17M | 0.66M | 1.19M | 1.06M |
| Cash | 15.28M | 12.66M | 27.27M | 14.68M | 87.97M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 13.77M | 18.51M | 17.64M | 13.61M | 15.93M |
| Current deferred revenue | 0.12M | 0.09M | 0.05M | 0.41M | 0.32M |
| Net debt | -4.85200M | 5.96M | -1.67500M | 15.07M | -75.98400M |
| Short term debt | 7.46M | 9.86M | 9.85M | 5.60M | 8.61M |
| Short long term debt | 5.76M | 8.80M | 8.73M | 4.63M | 8.61M |
| Short long term debt total | 10.42M | 18.62M | 25.60M | 29.76M | 11.99M |
| Other stockholder equity | 447.63M | 437.55M | 382.64M | 356.61M | 358.14M |
| Property plant equipment | 0.10M | 20.23M | 18.81M | 14.55M | 11.48M |
| Total current assets | 24.57M | 55.49M | 46.83M | 71.69M | 107.99M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | -35.89300M | -55.75000M | -41.41800M | 4.25M |
| Short term investments | 0.49M | 38.97M | 15.61M | 51.45M | 17.74M |
| Net receivables | 0.31M | 0.16M | 0.64M | 0.52M | 0.40M |
| Long term debt | - | 5.01M | 13.14M | 20.52M | 3.38M |
| Inventory | 1.18M | 1.11M | 1.63M | 3.29M | 0.85M |
| Accounts payable | 2.04M | 2.12M | 2.74M | 1.72M | 2.07M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | - | - | - | -9.55200M | -8.94400M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | 0.10M | 0.08M | 0.08M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | -438.48500M | -398.10600M | -345.01900M |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 0.25M | 2.17M | 0.66M | 1.19M | 1.06M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 22.92M | 22.40M | 19.46M | 19.67M | 12.54M |
| Capital lease obligations | 4.66M | 4.82M | 3.72M | 4.61M | - |
| Long term debt total | - | - | - | 20.52M | 3.38M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | 36.45M | -23.47500M | 34.14M | -33.09300M | -10.05800M |
| Change to liabilities | 0.00000M | 1.30M | -2.17900M | 1.12M | 1.38M |
| Total cashflows from investing activities | - | -26.12300M | 34.14M | -36.56300M | -10.87700M |
| Net borrowings | - | -8.83300M | -4.66700M | 12.48M | -7.71800M |
| Total cash from financing activities | -0.50700M | 41.51M | 16.96M | 14.45M | 75.03M |
| Change to operating activities | - | -1.27600M | -0.86300M | -0.24500M | 0.18M |
| Net income | 47.76M | -35.09900M | -40.37900M | -53.24000M | -47.14900M |
| Change in cash | 7.61M | -14.61100M | 12.59M | -73.29100M | 35.07M |
| Begin period cash flow | 12.66M | 27.27M | 14.68M | 87.97M | 53.08M |
| End period cash flow | 20.27M | 12.66M | 27.27M | 14.68M | 88.15M |
| Total cash from operating activities | -28.33100M | -30.00200M | -38.50500M | -51.18000M | -29.07500M |
| Issuance of capital stock | 8.22M | 44.72M | 21.34M | 1.23M | 81.53M |
| Depreciation | 1.65M | 1.97M | 1.85M | 1.67M | 0.57M |
| Other cashflows from investing activities | - | -0.82100M | -0.82100M | -33.09300M | -10.05800M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | -0.10700M | -0.29500M | 0.96M | -3.39200M | 0.10M |
| Change to account receivables | -0.14900M | 0.47M | -0.20300M | -0.38300M | 1.48M |
| Sale purchase of stock | -0.31500M | - | 21.71M | 1.98M | 82.74M |
| Other cashflows from financing activities | 0.26M | 5.63M | 0.29M | 25.55M | 1.22M |
| Change to netincome | -76.34300M | 2.92M | 2.31M | 5.59M | 4.97M |
| Capital expenditures | 0.36M | 1.83M | 1.85M | 3.47M | 0.82M |
| Change receivables | - | - | -0.20300M | -0.38300M | 1.48M |
| Cash flows other operating | - | - | -6.97200M | -3.25400M | 8.95M |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | 12.59M | -73.29100M | 35.07M |
| Change in working capital | -1.39000M | 0.20M | -2.28800M | -3.90600M | 1.87M |
| Stock based compensation | 2.89M | 4.61M | 4.42M | 5.06M | 5.17M |
| Other non cash items | -79.23200M | -2.49800M | -2.11500M | -1.71000M | 10.55M |
| Free cash flow | -28.69500M | -31.82900M | -40.36000M | -54.65000M | -29.89400M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| ACRX AcelRx Pharmaceuticals Inc |
- -% | - | - | 1.06 | 34.59 | 0.70 | 1.17 | -0.1131 |
| ZTS Zoetis Inc |
1.32 0.88% | 150.88 | 40.18 | 30.96 | 10.67 | 17.60 | 11.27 | 26.18 |
| MKKGY Merck KGaA ADR |
-0.46 1.40% | 32.44 | 21.25 | 14.93 | 3.10 | 2.14 | 3.60 | 12.98 |
| MKGAF MERCK Kommanditgesellschaft auf Aktien |
-2.142 1.33% | 158.36 | 21.73 | 14.95 | 3.16 | 2.15 | 3.56 | 12.82 |
| TAK Takeda Pharmaceutical Co Ltd ADR |
-0.15 1.12% | 13.23 | 32.67 | 11.53 | 0.01 | 0.87 | 0.02 | 0.07 |
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 clinical trial for the treatment of cancer breakthrough pain in opioid-tolerant patients; and ARX-03, which is in Phase 2 clinical trial for the treatment of procedural anxiety and acute pain. Its product candidates also include Niyad, a regional anticoagulant for the extracorporeal circuit; and LTX-608, a nafamostat formulation for direct IV infusion being explored as an investigational product for antiviral treatment of COVID, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis. The company also develops Fedsyra, an ephedrine pre-filled syringe that contains 10 ml of a solution of 3 mg/ml ephedrine hydrochloride for injection; and phenylephrine, a phenylephrine pre-filled syringe, which contains 10 ml of a solution of 50 mcg/ml phenylephrine for injection. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Hayward, California.
25821 Industrial Boulevard, Hayward, CA, United States, 94545
| Name | Title | Year Born |
|---|---|---|
| Mr. Vincent J. Angotti | CEO & Director | 1968 |
| Dr. Pamela Pierce Palmer M.D., Ph.D. | Co-Founder, Chief Medical Officer & Director | 1963 |
| Mr. Raffi Mark Asadorian | Chief Financial Officer | 1969 |
| Mr. Lawrence G. Hamel | Consultant | 1952 |
| Mr. Anil N. Dasu | Chief Engineering Officer | 1963 |
Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
US 
AU
UK
CA
NZ
Please wait processing your request...